About: Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System
Creator	Wang, Li Drph, Hurd, Yasmin Wang, An-Li Zhong, Xiaobo
source	MedRxiv
abstract	Background: New York City is the US epicenter of the coronavirus disease 2019 (COVID-19) pandemic. Early international data indicated that comorbidity contributes significantly to poor prognosis and fatality in patients infected with SARS-CoV-2. It is not known to what degree medical comorbidity and sociodemographic determinants impact COVID-19 mortality in the US. Methods: Evaluation of de-identified electronic health records of 7,592 COVID-19 patients confirmed by SARS-CoV-2 lab tests in New York City. Medical comorbidites and outcome of mortality, and other covariates, including clinical, sociodemographic, and medication measures were assessed by bivariate and multivariate logistic regression models. Results: Of common comorbid conditions (hypertension, chronic kidney disease, chronic obstructive pulmonary disease, asthma, obesity, diabetes, HIV, cancer), when adjusted for covariates, chronic kidney disease remained significantly associated with increased odds of mortality. Patients who had more than one comorbidities, former smokers, treated with Azithromycin without Hydroxychloroquine, reside within the boroughs of Brooklyn and Queens Higher had higher odds of death. Conclusions: Increasing numbers of comorbid factors increase COVID-19 mortality, but several clinical and sociodemographic factors can mitigate risk. Continued evaluation of COVID-19 in large diverse populations is important to characterize individuals at risk and improve clinical outcomes.
has issue date	2020-06-12(xsd:dateTime)
bibo:doi	10.1101/2020.06.11.20128926
has license	medrxiv
sha1sum (hex)	2c3d96b52b0dd200c246e8edded9e650574c63cd
schema:url	https://doi.org/10.1101/2020.06.11.20128926
resource representing a document's title	Comorbidity and Sociodemographic determinants in COVID-19 Mortality in an US Urban Healthcare System
resource representing a document's body	covid:2c3d96b52b0dd200c246e8edded9e650574c63cd#body_text
is schema:about of	named entity 'Urban' named entity 'Healthcare' covid:arg/2c3d96b52b0dd200c246e8edded9e650574c63cd named entity 'measures' named entity 'covariates' named entity 'New York City' named entity 'asthma' named entity 'respiratory rate' named entity 'chronic kidney disease' named entity 'Hydroxychloroquine' named entity 'models' named entity 'COVID-19' named entity 'System' named entity 'Short title' named entity 'comorbidity' named entity 'COVID-19' named entity 'comorbidity' named entity 'Mount Sinai Health System' named entity 'China' named entity 'Hydroxychloroquine' named entity 'COVID-19' named entity 'comorbidity' named entity 'New York City' named entity 'preprint' named entity 'zip code' named entity 'Azithromycin' named entity 'preprint' named entity 'clinical outcomes' named entity 'sample size' named entity 'COVID-19' named entity 'Social determinants of health' named entity 'clinical trial' named entity 'comorbidities' named entity 'Hydroxychloroquine' named entity 'Vital signs' named entity 'COVID-19' named entity 'vital sign' named entity 'Respiratory rate' named entity 'peer review' named entity 'preprint' named entity 'Azithromycin' named entity 'diastolic' named entity 'preprint' named entity 'peer review' named entity 'logistic regression' named entity 'Hydroxychloroquine' named entity 'COVID-19' named entity 'risk factors' named entity 'long-term' named entity 'comorbidities' named entity 'infection' named entity 'socioeconomic status' named entity 'COVID-19' named entity 'case fatality rate' named entity 'clinical care' named entity 'Azithromycin' named entity 'SES' named entity 'case fatality rates' named entity 'Manhattan' named entity 'medRxiv' named entity 'comorbidities' named entity 'medRxiv' named entity 'kidney disease' named entity 'chronic kidney disease' named entity 'peer review' named entity 'electronic health records' named entity 'COVID-19' named entity 'mortality risk' named entity 'coronavirus disease 2019' named entity 'asthma' named entity 'comorbidities' named entity 'Azithromycin' named entity 'HIV' named entity 'medRxiv' named entity 'preprint' named entity 'preprint' named entity 'Brooklyn' named entity 'preprint' named entity 'preprint' named entity 'Hydroxychloroquine' named entity 'Ethnicity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software